创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels Biotechnology: Immunogenicity Assay Platform Technical Characteristics

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-04-28 15:00
  • Views:

(Summary description)As a bright pearl in the field of drug discovery and development, InnoModels' immunogenicity testing platform has attracted the attention of many research institutions and enterprises with its unique advantages and comprehensive service capabilities. With advanced testing technology and equipment, combined with an experienced and skilled team, the platform provides professional immunogenicity research services for drug R&D, escorting drug development.

InnoModels Biotechnology: Immunogenicity Assay Platform Technical Characteristics

(Summary description)As a bright pearl in the field of drug discovery and development, InnoModels' immunogenicity testing platform has attracted the attention of many research institutions and enterprises with its unique advantages and comprehensive service capabilities. With advanced testing technology and equipment, combined with an experienced and skilled team, the platform provides professional immunogenicity research services for drug R&D, escorting drug development.

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-04-28 15:00
  • Views:
Information

As a bright pearl in the field of drug discovery and development, InnoModels' immunogenicity testing platform has attracted the attention of many research institutions and enterprises with its unique advantages and comprehensive service capabilities. With advanced testing technology and equipment, combined with an experienced and skilled team, the platform provides professional immunogenicity research services for drug R&D, escorting drug development.
1. Ensure the accuracy and reliability of experimental results
InnoModels' immunogenicity testing platform adopts advanced testing technology and equipment to ensure the accuracy and reliability of experimental results. The platform introduces a series of international advanced testing instruments, such as flow cytometer, enzyme labeling instrument, immunohistochemistry instrument, etc., to provide accurate data support for the experiments. At the same time, the platform strictly follows the national and international standards, and has formulated a set of perfect experimental operation procedures and quality control system to ensure that each experimental link can reach the best state, so as to provide customers with the most accurate experimental results.

 


2、Experienced and skilled team
InnoModels Biotechnology immunogenicity testing platform has an experienced and skilled team with solid theoretical foundation and rich practical experience. They not only have profound attainments in the field of immunogenicity research, but also can keep up with the international cutting-edge technology and constantly update their knowledge to provide customers with the best quality services. This team always focuses on the customer, in-depth understanding of customer needs, and customized experimental solutions to ensure the practicality and operability of the experimental results.
3、Providing comprehensive immunogenicity assessment services
InnoModels' immunogenicity testing platform is capable of providing comprehensive immunogenicity assessment services, including cellular immunity, humoral immunity and ultrasensitive reaction research. The platform has a complete experimental technology system and can provide customers with one-stop services from sample processing, experimental design, data analysis to result interpretation. At the same time, the platform can also provide personalized experimental solutions according to the needs of customers to meet the different needs of customers in the process of drug development.
All in all, with its advanced technical equipment, professional team and comprehensive service capability, InnoModels' immunogenicity testing platform provides strong support for the drug discovery and development field. In the future, InnoModels Biotechnology will continue to adhere to the concept of "professionalism, innovation, service and win-win", continuously optimize and improve the platform services, provide more customers with better and more efficient immunogenicity testing services, and help the global drug discovery and development business to achieve even more brilliant achievements.
In this ever-changing technological era, InnoModels' immunogenicity testing platform will keep up with international cutting-edge technologies, actively expand new research fields, and provide more diversified and higher-quality testing services for drug discovery and development. At the same time, the platform will also strengthen cooperation and communication with domestic and foreign research institutions and enterprises to jointly promote technological progress and industrial upgrading in the field of drug R&D.
In the future development, InnoModels Biotechnology immunogenicity testing platform will continue to play its important role in the field of drug R&D and provide strong technical support for more research projects and enterprises. It is believed that with the efforts of InnoModels Biotechnology, drug R&D will achieve even more impressive results and contribute more to the development of human health.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司